Search results for "CLO"

showing 10 items of 9986 documents

The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.

2021

medicine.medical_specialtyDrug Industrybusiness.industryGeneral NeuroscienceMEDLINEGeneral MedicineDiseaseAntibodies Monoclonal HumanizedRaising (linguistics)United StatesPsychiatry and Mental healthClinical PsychologyAlzheimer DiseaseMedicineHumansAducanumabGeriatrics and GerontologybusinessIntensive care medicineDrug ApprovalJournal of Alzheimer's disease : JAD
researchProduct

Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in Fran…

2018

Background One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in the United Kingdom but not in the rest of the world was that it would result in more deaths from fatal adverse drug reactions (ADRs) than the number of IE deaths. The main aim of this study was to quantify and describe the ADRs with amoxicillin or clindamycin for IE AP. The second aim was to infer a crude incidence of anaphylaxis associated with amoxicillin for IE AP. Material and Methods The Medical Dictionary for Regulatory Activities (MedDRA) was used to group ADRs for IE AP using the broad Standardized MedDRA Queries “Anaphylactic reaction, Amoxicillin, Clindamycin, Clostrid…

medicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsMedDRA03 medical and health sciences0302 clinical medicineInternal medicinePharmacovigilanceHumansMedicineEndocarditisAntibiotic prophylaxisGeneral DentistryOral Medicine and PathologyEndocarditisbusiness.industryResearchClindamycinEndocarditis Bacterial030206 dentistryAntibiotic ProphylaxisAmoxicillinClostridium difficilemedicine.disease:CIENCIAS MÉDICAS [UNESCO]3. Good healthOtorhinolaryngologyInfective endocarditisUNESCO::CIENCIAS MÉDICASSurgeryFrancebusinessmedicine.drug
researchProduct

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

2015

PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse events. This spectrum is different from toxicities known for kinase inhibitors or cytotoxic drugs. Since PD-1 directed therapies show effectivity in an increasing number of malignant diseases, their clinical usage will increase rapidly. Therefore clinicians from different specialities such as medical oncology, internal medicine, family doctors and emergency unit staff should be aware of the adverse effects of PD-1 checkpoint inhibitors to avoid delays in diagnosis and treatment. Based on pooled data from pivotal trials as reported by the European Medicines Agency, the present paper reviews incidence…

medicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMedizinAntineoplastic AgentsPembrolizumabAntibodies Monoclonal HumanizedB7-H1 Antigen03 medical and health sciences0302 clinical medicineRefractoryMonitoring ImmunologicNeoplasmsmedicineEndocrine systemHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineAdverse effectbusiness.industryAntibodies MonoclonalDisease ManagementGeneral MedicineImmunotherapymedicine.diseaseEarly DiagnosisNivolumabOncologyMethylprednisolone030220 oncology & carcinogenesisImmunologyNivolumabbusinessAdverse drug reactionImmunosuppressive Agentsmedicine.drugCancer treatment reviews
researchProduct

Chronic oral haloperidol and clozapine in rats: A behavioral evaluation.

1999

The present study evaluated chronic oral treatment of rats with haloperidol or clozapine. Drugs were given in the drinking water for a 23-day period . Rat behavior was analyzed once a week in an open field. Rats ingested either 1.7 mg/kg haloperidol or 40 mg/kg clozapine daily. Blood serum analysis revealed concentrations of 6 ng/ml for haloperidol and 22 ng/ml for clozapine at the end of the treatment. Haloperidol decreased overall activity from the onset of treatment. Clozapine showed similar effects only on the last test day. Control animals showed a slight habituation in exploration-related parameters. In conclusion, these results indicate that oral drug administration through the drink…

medicine.medical_specialtyDyskinesia Drug-InducedTime FactorsAdministration OralPharmacologyWeight GainOpen fieldRats Sprague-DawleyBlood serumOral administrationInternal medicinemedicineHaloperidolAnimalsHabituationHabituation PsychophysiologicClozapineBiological PsychiatryClozapineAnalysis of VarianceBehavior Animalbusiness.industryAntagonistRatsPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologyExploratory BehaviorHaloperidolFemaleAnalysis of variancebusinessLocomotionmedicine.drugAntipsychotic AgentsNeuropsychobiology
researchProduct

P1699Non-ST segment elevation miocardial infarction (NSTEMI) vs. Unstable angina (UA) in young women aged < 45 years - differences in symptomatolo…

2019

Abstract Background Almost 50% of all ACS in young women are NSTEMI and UA. Due to the type of ACS we observed differences in the symptomatology, treatment and outcomes. The aim was to evaluate the differences in the clinical course and prognosis in young women aged ≤45 years with NSTEMI vs. UA. Methods We compared 1143 women aged ≤45y.o. with acute cardiac syndromes: 51% NSTEMI, 49% UA from the PL-ACS registry between 2007 - 2014. Results Chest pain was predominant in both group, with a higher incidence in NSTEMI group (91.7% vs. 84.7, p=0.0002). UA group was older (42y.o. vs. 41y.o p=0.003), more often presents atypical symptoms (8.0% vs. 1.5%, p<0,0001) mostly with dyspnea (3.9%vs. 1.…

medicine.medical_specialtyEjection fractionUnstable anginabusiness.industryInfarctionClopidogrelmedicine.diseaseChest painRestenosisInternal medicineCardiologymedicineST segmentmedicine.symptomCardiology and Cardiovascular MedicinebusinessKillip classmedicine.drugEuropean Heart Journal
researchProduct

Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone Resorption

2000

Human serum contains two forms of tartrate-resistant acid phosphatase (TRAP), 5a and 5b. Of these, 5a contains sialic acid and 5b does not. We show here that antigenic properties and pH optimum of TRAP purified from human osteoclasts are identical to those of serum TRAP 5b and completely different from those of serum TRAP 5a, suggesting that 5b would be derived from osteoclasts and 5a from some other source. We developed a novel immunoassay specific for 5b using a monoclonal antibody O1A as capture antibody. O1A did not bind acid phosphatase derived from platelets and erythrocytes. Western analysis showed that O1A was specific for TRAP in both human bone and serum. We measured bound TRAP ac…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismAcid PhosphataseNeuraminidaseBone resorptionPlaceboschemistry.chemical_compoundDouble-Blind MethodReference ValuesOsteoclastInternal medicineEnzyme StabilitymedicineHumansOrthopedics and Sports MedicineBone ResorptionIncubationTartrate-resistant acid phosphataseEstradiolmedicine.diagnostic_testbiologyTartrate-Resistant Acid PhosphataseEstrogen Replacement TherapyAcid phosphataseAntibodies MonoclonalMiddle AgedSialic acidResorptionIsoenzymesPostmenopauseEndocrinologymedicine.anatomical_structurechemistryImmunoassaybiology.proteinFemaleNorethindroneBiomarkersJournal of Bone and Mineral Research
researchProduct

Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

2019

Background: Age, smoking, hypercholesterolemia, and hypertension are major risk factors for atherosclerotic cardiovascular disease. Objective: We examined whether the effects of alirocumab on low-density lipoprotein cholesterol (LDL-C) differed according to age, hypertension, or smoking status. Methods: Data were pooled from 10 Phase 3 ODYSSEY randomized trials (24–104 weeks’ duration) in 4983 people with heterozygous familial hypercholesterolemia (FH) or non–familial hypercholesterolemia (3188 on alirocumab, 1795 on control [620 on ezetimibe and 1175 on placebo]). Most participants received concomitant maximum tolerated statin therapy. In 8 trials, the alirocumab dose was increased from 75…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedPlacebolaw.inventionPCSK903 medical and health sciencesAge0302 clinical medicineRandomized controlled trialEzetimibeRisk FactorslawInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineAdverse effectAgedAlirocumabNutrition and Dieteticsbusiness.industryPCSK9SmokingAge FactorsCholesterol LDLMiddle Agedmedicine.diseaseCholesterolTreatment OutcomeConcomitantHypertensionCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Clinical Lipidology
researchProduct

Mathematical Modelling of Local Regulation of Blood Flow by Veno-Arterial Diffusion of Vasoactive Metabolites

1997

It is widely accepted that vasoactive substances which are consumed or produced by tissue metabolism play a role in the adjustment of local perfusion rate to the metabolic needs of the tissue. In order to evoke a response of the vascular system, these substances — in the following for simplicity denoted by “vasodilators” even though oxygen, for example, is a vasoconstrictor — need to get into close contact with the small arterioles which represent the most powerful effectors in perfusion control. On the other hand, tissue sites in which supply with nutrients is most critical (“lethal corners”) and in which a vasodilator signal may be generated earliest, are located hundreds of µm away from …

medicine.medical_specialtyEndocrinologyPerfusion rateVasoactiveInternal medicinemedicineBiophysicsVasodilationBlood flowDiffusion (business)PerfusionBlood streamClose contact
researchProduct

Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2

2005

Objective To examine the effects of raloxifene on prostacyclin production by human umbilical vein endothelial cells (HUVEC) and to shed light on the molecular details of that action. Design Cell culture for 4, 8, 16, 24, and 48 hours. Setting University research laboratory. Patient(s) Source of HUVEC. Intervention(s) Measurement of prostacyclin production and of protein levels and mRNA expression of cyclooxygenase (COX)-1 and -2. Main Outcome Measure(s) Prostacyclin production was measured by enzyme immunoassay, the mRNA expression of COX-1 was measured by quantitative real time-polymerase chain reaction, and the protein levels of COX-1 and -2 were measured by immunoblotting. Result(s) Ralo…

medicine.medical_specialtyEndotheliumAgonist-antagonistEstrogen receptorProstacyclinPharmacologyGene Expression Regulation EnzymologicUmbilical veinInternal medicinemedicineHumansCyclooxygenase InhibitorsRaloxifeneCells CulturedDose-Response Relationship DrugbiologyChemistryEndothelial CellsObstetrics and GynecologyEpoprostenolEndothelial stem cellmedicine.anatomical_structureEndocrinologyReproductive MedicineCyclooxygenase 2Raloxifene HydrochlorideCyclooxygenase 1biology.proteinCyclooxygenasemedicine.drugFertility and Sterility
researchProduct

Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A

1998

Abstract Background The antipsoriatic drugs cyclosporin A (CyA) and etretinate have been found to influence proinflammatory eosinophilic leukocytes and pruritus. Aim We compared the number of blood eosinophils, concentration of serum eosinophil cationic protein (ECP), and pruritus in patients with psoriasis treated with either CyA or etretinate. Study design Patients with psoriasis vulgaris were randomly assigned to treatment for 10 weeks with either CyA ( n =21) or etretinate ( n =10). The psoriasis area-and-severity index (PASI-score) and pruritus (according to a 0–3 scale) served as clinical parameters, the blood esosinophil counts (Coulter Counter) and the serum ECP (RIA, Pharmacia) as …

medicine.medical_specialtyEosinophil cationic proteinbusiness.industryKeratolyticEtretinateDermatologymedicine.diseaseGastroenterologyBlood proteinsProinflammatory cytokineInfectious DiseasesPsoriasisInternal medicineCyclosporin aEosinophilicImmunologymedicinebusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct